Pain News and Research

Latest Pain News and Research

Fainting may point to more serious, underlying cardiovascular condition

For those who suffer from fainting spells, the mysterious episodes can be quite scary. Far too often, fainting is chalked up to stress or other mental health issues. However, medical experts at Rush University Medical Center say that reoccurring fainting spells, also known as syncope, could be an important symptom that can point to a more serious, underlying cardiovascular condition.

10 Aug 2009

Traditional Chinese acupuncture affects the brain's long-term ability to regulate pain

Acupuncture has been used in East-Asian medicine for thousands of years to treat pain, possibly by activating the body's natural painkillers. But how it works at the cellular level is largely unknown.

10 Aug 2009

Gallbladder emptying in primary sclerosing cholangitis patients

Primary sclerosing cholangitis (PSC) is an idiopathic chronic cholestatic inflammatory liver disease characterized by diffuse fibrosing inflammation of intra- and/or extrahepatic bile ducts, resulting in bile duct obliteration, biliary cirrhosis, and eventually hepatic failure. One of the most common symptoms at the time of presentation of PSC is mild to severe abdominal pain localized in the right upper quadrant. However, the mechanisms responsible for the abdominal pain in PSC are not fully understood.

10 Aug 2009

Vulvodynia, the most frequent cause of painful sex

PAINFUL SEX. It's a secret that millions of women live with in embarrassment and isolation. Until now. . .

10 Aug 2009

Research explains why women report more sleep disruption than men

Even with growing progress toward gender equality in the workplace, women continue to carry the most responsibility for family care, a load that according to a new study could indicate why women report more sleep disruption than men.

10 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Sharing prescription advice among adolescents can have dangerous repercussions

What if a teenager with acne who is taking Accutane - a drug linked to birth defects - gives some to her friend, who is pregnant but does not yet realize it? Unfortunately, this is a realistic scenario.

10 Aug 2009

Transcranial MR-guided focused ultrasound for brain disorders a step closer

A team of researchers working at the MR-Center of the University Children's Hospital in Zürich has completed a pilot study using transcranial MR-guided focused ultrasound to treat 10 patients with neuropathic pain.

9 Aug 2009

New journal integrates the science of medicine with the art of music

In response to a recent surge in studies that integrate medicine and music, SAGE, the world's leading independent academic and professional publisher, is pleased to launch Music and Medicine in July, a new interdisciplinary journal that will incorporate the research that combines the two disciplines.

9 Aug 2009

Watson recalls one lot of Fentanyl transdermal system

Watson Pharmaceuticals has announced that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies.

9 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

Psoriasis sufferers at risk for other medical conditions

Emerging research reveals that people with psoriasis are at risk for developing other serious medical conditions including heart disease, diabetes and obesity. According to a new study by the National Psoriasis Foundation, of 5,000 people with psoriasis, nearly two-thirds report having at least one other critical health problem.

6 Aug 2009

Percutaneous vertebroplasty exposed as ineffective

A world-first study involving Monash University and the Cabrini Research Institute in Melbourne has revealed the injection of bone cement into broken vertebrae is not an effective treatment for patients suffering painful osteoporotic fractures.

6 Aug 2009

Comparative effectiveness studies raise questions about vertebroplasty back pain treatment

New studies on treating back pain from a fractured spine could call more attention to the type of comparative effectiveness research health policy experts and President Barack Obama have embraced in their quest to increase quality of care while lowering costs.

6 Aug 2009

Health reform still worth fighting for

The news about health care is a little confusing these days. While polls show that Americans still support the key elements of health care reform that President Obama and his allies are trying to enact, there have been numerous reports of conservative activists showing up at congressional town halls across the country, protesting those same plans with an energy not matched by the other side.

6 Aug 2009

Bill Clinton, Pfizer, and Mylan announce new agreements to lower prices of antiretrovirals for HIV/AIDS in the developing world

President Bill Clinton announced two important and complementary agreements today to enable better, more affordable treatments for patients on second-line antiretroviral (ARV) therapy for HIV/AIDS in the developing world.

6 Aug 2009

Experts on vertebroplasty contend recent vertebroplasty studies are misleading

Two studies released today in the New England Journal of Medicine claim to demonstrate that vertebroplasty, a procedure to treat some painful spine fractures, is not effective. This is incorrect, as both studies actually demonstrate a significant improvement in patients' pain and ability to function normally.

6 Aug 2009

Spectrum Pharmaceuticals acquires rights and IP for Renazorb

Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.

6 Aug 2009

Orexo: Abstral NDA submitted to U.S. FDA

Orexo AB has announced that its partner, UK-based international specialty pharmaceutical company ProStrakan Group plc, has submitted the New Drug Application (NDA) for Abstral™ (for the treatment of breakthrough cancer pain in opioid-tolerant patients) to the US Food and Drug Administration (FDA).

6 Aug 2009

New insights into peripheral artery disease

Walking is a painful experience for many of the eight million Americans who suffer lower extremity peripheral arterial disease, or PAD. The condition, which is associated with aging and involves progressive functional decline, can cause heaviness, tightness, cramping or sharp pain in the calf muscle. Symptoms typically disappear with rest and return when walking resumes.

5 Aug 2009